Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00313586
First received: April 11, 2006
Last updated: November 18, 2014
Last verified: April 2014
Results First Received: November 18, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia (Dysplastic Type)
Acute Myeloid Leukemia With Multilineage Dysplasia
Interventions: Drug: entinostat
Drug: azacitidine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were recruited from ECOG member institutions between August 18, 2006 and April 29, 2011. One hundred and fifty non-treatment-induced patients and forty-seven treatment-induced patients were enrolled.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Arm A (Azacitidine; Non-treatment-induced Cohort) Non-treatment-induced patients receive azacitidine (50 mg/m2) subcutaneously once daily on days 1-10 in a 28-day cycle.
Arm B (Azacitidine + Entinostat; Non-treatment-induced Cohort) Non-treatment-induced patients receive azacitidine as in arm A and oral entinostat (4 mg/m2) on days 3 and 10 of each 28-day cycle.
Arm A (Azacitidine; Treatment-induced Cohort) Treatment-induced patients receive azacitidine (50 mg/m2) subcutaneously once daily on days 1-10 in a 28-day cycle.
Arm B (Azacitidine + Entinostat; Treatment-induced Cohort) Treatment-induced patients receive azacitidine as in arm A and oral entinostat (4 mg/m2) on days 3 and 10 of each 28-day cycle.

Participant Flow:   Overall Study
    Arm A (Azacitidine; Non-treatment-induced Cohort)     Arm B (Azacitidine + Entinostat; Non-treatment-induced Cohort)     Arm A (Azacitidine; Treatment-induced Cohort)     Arm B (Azacitidine + Entinostat; Treatment-induced Cohort)  
STARTED     75     75     24     23  
Treated     74     75     24     23  
COMPLETED     5     5     0     0  
NOT COMPLETED     70     70     24     23  
Disease progression                 14                 19                 10                 3  
Adverse Event                 12                 18                 3                 10  
Death                 11                 8                 1                 7  
Withdrawal by Subject                 13                 6                 6                 2  
Alternative therapy                 3                 6                 2                 0  
Other complicating disease                 2                 2                 0                 0  
Did not achieve HI-major/better response                 10                 7                 2                 1  
Physician Decision                 2                 1                 0                 0  
Absolute neutrophil count not recovered                 2                 1                 0                 0  
Lost insurance                 0                 1                 0                 0  
Moved                 0                 1                 0                 0  
Death before starting treatment                 1                 0                 0                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All treated patients were included in the analysis.

Reporting Groups
  Description
Arm A (Azacitidine; Non-treatment-induced Cohort) Non-treatment-induced patients receive azacitidine (50 mg/m2) subcutaneously once daily on days 1-10 in a 28-day cycle.
Arm B (Azacitidine + Entinostat; Non-treatment-induced Cohort) Non-treatment-induced patients receive azacitidine as in arm A and oral entinostat (4 mg/m2) on days 3 and 10 of each 28-day cycle.
Arm A (Azacitidine; Treatment-induced Cohort) Treatment-induced patients receive azacitidine (50 mg/m2) subcutaneously once daily on days 1-10 in a 28-day cycle.
Arm B (Azacitidine + Entinostat; Treatment-induced Cohort) Treatment-induced patients receive azacitidine as in arm A and oral entinostat (4 mg/m2) on days 3 and 10 of each 28-day cycle.
Total Total of all reporting groups

Baseline Measures
    Arm A (Azacitidine; Non-treatment-induced Cohort)     Arm B (Azacitidine + Entinostat; Non-treatment-induced Cohort)     Arm A (Azacitidine; Treatment-induced Cohort)     Arm B (Azacitidine + Entinostat; Treatment-induced Cohort)     Total  
Number of Participants  
[units: participants]
  74     75     24     23     196  
Age  
[units: years]
Median ( Full Range )
  72  
  ( 25 to 87 )  
  72  
  ( 30 to 86 )  
  68  
  ( 54 to 83 )  
  71  
  ( 39 to 81 )  
  71  
  ( 25 to 87 )  
Gender  
[units: participants]
         
Female     24     23     15     11     73  
Male     50     52     9     12     123  
Region of Enrollment  
[units: participants]
         
United States     74     75     24     23     196  



  Outcome Measures

1.  Primary:   Proportion of Patients With Clinical Response   [ Time Frame: Assessed every 3 months if patient is < 2 years from study entry, every 6 months if patient is 2 - 5 years from study entry. ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Study Statistician
Organization: ECOG Statistical Office
phone: 617-632-3012


Publications of Results:

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00313586     History of Changes
Other Study ID Numbers: NCI-2009-01077, NCI-2009-01077, E1905, U10CA021115
Study First Received: April 11, 2006
Results First Received: November 18, 2014
Last Updated: November 18, 2014
Health Authority: United States: Food and Drug Administration